SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Pharmaceutical Investing
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS for the Treatment of Lupus Nephritis Pharmaceutical Investing
AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 Pharmaceutical Investing
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings Pharmaceutical Investing
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937 Pharmaceutical Investing
New Research for KEYTRUDA® at Society for Melanoma Research 2021 Congress Reinforces Merck's Commitment to Patients With Melanoma Across Stages of Disease Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, EAR, HYZN, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years Pharmaceutical Investing
U.S. Food and Drug Administration Approves VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia Pharmaceutical Investing
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc. Pharmaceutical Investing
AbbVie's Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder Pharmaceutical Investing
